Patents Examined by Lei Yao
  • Anti-Galectin-9 antibodies and uses thereof
    Patent number: 10344091
    Abstract: Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: July 9, 2019
    Assignees: New York University, PureTech Health, LLC
    Inventors: Shohei Koide, George Miller, Akiko Koide, Linxiao Chen, Eric Elenko, Aleksandra Filipovic, Joseph Bolen
  • Immunogenic compositions comprising progastrin and uses thereof
    Patent number: 10335470
    Abstract: The present invention is drawn to immunotherapeutic methods to treat tumors/cancers that produce progastrin ectopically or are dependent on progastrin for their growth. Disclosed herein are immunogenic compositions comprising agents that target progastrin, agents that target the progastrin receptor, annexin II, or both. Such a composition may be administered in combination with chemotherapy or to an individual who had been previously subjected to chemotherapy or radiation therapy. The cancers that may be treated using such a composition may include but are not limited to colon cancer, breast cancer, lung cancer or pancreatic cancer.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: July 2, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Pomila Singh, Gurpreet Singh
  • Bladder cancer specific ligand peptides
    Patent number: 10335365
    Abstract: The present invention is directed to bladder cancer specific ligand peptides, comprising the amino acid sequence X1DGRX5GF (SEQ ID NO: 1), and methods of their use, e.g., for imaging detection for diagnosis of bladder, tumor localization to guide transurethral resection of bladder cancer, imaging detection of bladder cancer for follow-up after the initial treatment that can replace or complement costly cystoscopy, imaging detection of metastatic bladder cancer, and targeted therapy for superficial and metastatic bladder cancer.
    Type: Grant
    Filed: January 7, 2017
    Date of Patent: July 2, 2019
    Assignees: The Regents ot the Univershy of California, The United States of America as represented by the Department of Veteran Affairs (Washington DC)
    Inventors: Chong-Xian Pan, Hongyong Zhang, Kit S. Lam, Olulanu H. Aina
  • Method of detecting cancer
    Patent number: 10338072
    Abstract: The disclosure provides methods for resolving an inconclusive cytological assessment of clinically relevant cells in a sample obtained from a patient based on the cytological detection of antibody binding to telomerase in clinically relevant cells in the sample, wherein binding of the antibody to clinically relevant cells indicates the presence of malignant or cancerous cells.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: July 2, 2019
    Assignee: Sienna Cancer Diagnostics Ltd
    Inventors: Minesh Lalla, Fabio Turatti, Sharyn Wilson
  • Tumor cell-derived microvesicles
    Patent number: 10317407
    Abstract: The present invention relates to a method for diagnosis of cancer and for monitoring the progression of cancer and/or the therapeutic efficacy of an anti-cancer treatment in a sample of a subject by detecting oncogenic proteins in microvesicles, and to the use of an agent blocking exchange of microvesicles for treating cancer.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: June 11, 2019
    Assignees: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY, THE HOSPITAL FOR SICK CHILDREN
    Inventors: Janusz Rak, Khalid Al-Nedawi, Brian Meehan, Abhijit Guha
  • Identification of surface-associated antigens for tumor diagnosis and therapy
    Patent number: 10302647
    Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: May 28, 2019
    Assignee: BIONTECH AG
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Gerd Helftenbein, Dirk Usener, Volker Schluter
  • Breast and ovarian cancer vaccines
    Patent number: 10293035
    Abstract: The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids. The compositions may comprise peptides. The methods described herein include administering a composition comprising an epitope of a peptide to a subject in need thereof.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: May 21, 2019
    Assignee: University of Washington through its Center for Commercialization
    Inventors: Mary L. Disis, Denise Cecil, Meredith Slota
  • Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
    Patent number: 10294288
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: May 21, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer
    Patent number: 10280468
    Abstract: Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: May 7, 2019
    Assignee: Almac Diagnostics Limited
    Inventors: Denis Paul Harkin, Richard Kennedy, Katherine E. Keating, Andrena McCavigan, Laura A. Hill, Steve Deharo, Timothy Davison, Fionnuala Patterson, Sinead Donegan, Gera Jellema, Charlie Gourley
  • Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
    Patent number: 10273282
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: April 30, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Methods of producing antibodies specific for p95
    Patent number: 10273308
    Abstract: The disclosure provides methods of making antibodies specific for p95.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: April 30, 2019
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Jeff Sperinde, John William Winslow, Xueguang Jin, Gerald J. Wallweber
  • Methods for treating cancer in patients with elevated levels of BIM
    Patent number: 10259875
    Abstract: Materials and methods for treating cancer especially in patients identified as having elevated levels of Bim are disclosed. Specifically, the disclosure provides a method for treating a mammal having cancer, the method comprises: (a) identifying said mammal as containing an elevated level of Bim, and (b) administering to said mammal an anti-B7-H1 antibody, an anti-PD-1 antibody, an anti-CD80 antibody, or a fusion protein comprising a portion of PD1 or a portion of CD80, under conditions wherein the interaction of naturally occurring B7-H1 with PD-1 or CD80 in said mammal is reduced after said administering.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: April 16, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Haidong Dong, Susan M. Harrington, Eugene D. Kwon, Christopher J. Krco, Xin Liu
  • Anti-TIM-3 antibodies
    Patent number: 10259874
    Abstract: Anti-TIM-3 antibodies are disclosed, as well as pharmaceutical compositions comprising such antibodies, and uses and methods using the same, such as in the treatment of cancer, infectious diseases, or T-cell dysfunctional disorders. Bispecific antibodies against TIM-3 and other targets are also disclosed, with preferred embodiment of a bispecific antibody against TIM-3 and CD3.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: April 16, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Cheng-I Wang, Hsueh Ling Janice Oh, Siok Ping Yeo, Yun Pei Sharon Goh
  • Mutated antibody of fully humanized HER2 antibody, and encoding gene and use thereof
    Patent number: 10253108
    Abstract: The present invention provides a mutated antibody of the fully humanized HER2 antibody GB235-019, wherein the amino acid sequence of the heavy chain variable region and the amino acid sequence of the light chain variable region of the mutated antibody are respectively SEQ ID NO: 10, SEQ ID NO: 2; SEQ ID NO: 11, SEQ ID NO: 2; or SEQ ID NO: 12, SEQ ID NO: 2. The mutated antibody has the ability to specifically bind to human HER2 antigen, similar to the GB235-019 antibody. They can also be used in combination with additional HER2 positive tumor therapeutic agents for treating HER2 positive tumor, weakly positive tumor or negative tumor.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: April 9, 2019
    Assignee: Genor Biopharma Co., Ltd.
    Inventors: Qing Zhou, Mengjun Shu, Zhuzi He, Jun Lin
  • Glyco-engineered antibodies
    Patent number: 10253098
    Abstract: The present invention relates to an antibody preparation comprising modified antibodies of an animal or derivatives or fragments thereof, specific for an antigen, characterized in that the antibodies or derivatives or fragments thereof comprise an N-glycan structure free of fucose and xylose, and at least 90%, preferably at least 95%, more preferred at least 99%, most preferred at least 100% of the modified antibodies, derivatives or fragments thereof lack a C-terminal lysine residue.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: April 9, 2019
    Assignee: GREENOVATION BIOTECH GMBH
    Inventors: Manfred Schuster, Ralf Kircheis, Andreas Nechansky, Wolfgang Jost, Gilbert Gorr
  • Antibody binding to carbonic anhydrase and use thereof
    Patent number: 10246517
    Abstract: Provided is an antibody that recognizes and binds to carbonic anhydrase or antigen-binding fragment, a nucleic acid molecule coding for the antibody or antigen-binding fragment, a vector carrying the nucleic acid molecule, a host cell including the nucleic acid molecule or the vector, and use of the antibody or antigen-binding fragment thereof in the alleviation, prevention, treatment or diagnosis of solid cancers.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: April 2, 2019
    Assignee: APROGEN KIC INC.
    Inventors: Yoo Ri Moon, Gil Yong Ji
  • Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
    Patent number: 10239930
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: March 26, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Cancer vaccines and vaccination methods
    Patent number: 10226519
    Abstract: Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: March 12, 2019
    Assignee: Cedars-Sinai Medical Center
    Inventors: John S. Yu, Gentao Liu, Keith L. Black
  • Ubiquitinylated proteins
    Patent number: 10226518
    Abstract: A method of inducing a specific immune response in a mammal, comprising: providing a first composition comprising isolated ubiquitinylated proteins in solution in the absence of membrane bound organelles, the isolated ubiquitinylated proteins comprising one or more specific antigens, and further comprising a threshold quantity of polyubiquitinylated short-lived proteins and polyubiquitinylated defective ribosomal products. The isolated ubiquitinylated proteins are affinity-purified from tumor-derived cells grown in culture, the tumor-derived cells being inhibited from degrading ubiquitinylated proteins via the proteasome while being grown in culture. In this way, highly immunogenic short-lived proteins and defective ribosomal products may be loaded onto dendritic cells for cross-presentation and priming of antigen-specific T cells restricted by either classical or non-classical MHC.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: March 12, 2019
    Assignees: UbiVac, LLC, Providence Health & Science—Oregon
    Inventors: Christopher Twitty, Erik LeShane, Bernard Fox, Hong-Ming Hu, Guangjie Yu
  • Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
    Patent number: 10221229
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: March 5, 2019
    Assignee: INMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh